43 results on '"Pettit SJ"'
Search Results
2. Erratum to “Economic and environmental impacts of alternative routing scenarios in the context of China's belt and road initiative”: [Maritime Transport Research, volume 2 (2021) 100030]
- Author
-
Haider, J, Sanchez Rodrigues, V, Pettit, SJ, Harris, I, Beresford, AKC, and Shi, Y
- Published
- 2022
- Full Text
- View/download PDF
3. The statutory approach to coastal defence in England and Wales
- Author
-
Pettit, SJ, primary
- Published
- 1999
- Full Text
- View/download PDF
4. The land-based jobs market for seafarers
- Author
-
Gardner, BM, primary and Pettit, SJ, additional
- Published
- 1999
- Full Text
- View/download PDF
5. Seafarers and the land based jobs market
- Author
-
Gardner, BM, primary and Pettit, SJ, additional
- Published
- 1999
- Full Text
- View/download PDF
6. Letter by pettit et Al regarding article, 'electrical heart activity recorded during prolonged avalanche burial'.
- Author
-
Pettit SJ, Chaggar PS, and Windsor JS
- Published
- 2012
- Full Text
- View/download PDF
7. Prognostic value of three iron deficiency definitions in patients with advanced heart failure.
- Author
-
Papadopoulou C, Reinhold J, Grüner-Hegge N, Kydd A, Bhagra S, Parameshwar KJ, Lewis C, Martinez L, and Pettit SJ
- Subjects
- Humans, Prognosis, Iron, Transferrins, Anemia, Iron-Deficiency diagnosis, Anemia, Iron-Deficiency epidemiology, Heart Failure diagnosis, Heart Failure epidemiology, Heart Failure etiology, Iron Deficiencies
- Abstract
Aims: There is uncertainty about the definition of iron deficiency (ID) and the association between ID and prognosis in patients with advanced heart failure. We evaluated three definitions of ID in patients referred for heart transplantation., Methods and Results: Consecutive patients assessed for heart transplantation at a single UK centre between January 2010 and May 2022 were included. ID was defined as (1) serum ferritin concentration of <100 ng/ml, or 100-299 ng/ml with transferrin saturation <20% (guideline definition), (2) serum iron concentration ≤13 μmol/L, or (3) transferrin saturation <20%. The primary outcome measure was a composite of all-cause mortality, urgent heart transplantation or need for mechanical circulatory support. Overall, 801 patients were included, and the prevalence of ID was 39-55% depending on the definition used. ID, defined by either serum iron or transferrin saturation, was an independent predictor of the primary outcome measure (hazard ratio [HR] 1.532, 95% confidence interval [CI] 1.264-1.944, and HR 1.595, 95% CI 1.323-2.033, respectively), but the same association was not seen with the guideline definition of ID (HR 1.085, 95% CI 0.8827-1.333). These findings were robust in multivariable Cox regression analysis. ID, by all definitions, was associated with lower 6-min walk distance, lower peak oxygen consumption, higher intra-cardiac filling pressures and lower cardiac output., Conclusions: Iron deficiency, when defined by serum iron concentration or transferrin saturation, was associated with increased frequency of adverse clinical outcomes in patients with advanced heart failure. The same association was not seen with guideline definition of ID., (© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
8. High-sensitivity Cardiac Troponin Is Not Associated With Acute Cellular Rejection After Heart Transplantation.
- Author
-
Fitzsimons SJ, Evans JDW, Rassl DM, Lee KK, Strachan FE, Parameshwar J, Mills NL, and Pettit SJ
- Subjects
- Biomarkers, Biopsy, Graft Rejection diagnosis, Humans, Heart Transplantation adverse effects, Troponin I
- Abstract
Background: Acute cellular rejection (ACR) is common in the first year after cardiac transplantation, and regular surveillance endomyocardial biopsy (EMB) is required. An inexpensive, simple noninvasive diagnostic test would be useful. Prior studies suggest cardiac troponin (cTn) has potential as a "rule-out" test to minimize the use of EMB. Our aim was to determine whether a new high-sensitivity cardiac troponin I (hs-cTnI) assay would have utility as a "rule-out" test for ACR after heart transplantation., Methods: Blood samples at patient follow-up visits were collected and stored over a period of 5 y. Serum cTnI concentrations were measured using the ARCHITECTSTAT hs-cTnI assay and compared with an EMB performed on the same day. Receiver-operator curve analysis based on mixed-effects logistic regression models that account for repeated measurements in individuals was performed to determine a serum troponin level below which ACR could be reliably excluded., Results: One hundred seventy patients had 883 serum hs-cTnI results paired to a routine surveillance EMB. Fifty-one (6%) EMB showed significant ACR (grade ≥2R). Receiver-operator curve analysis approximated the null hypothesis area under the curve 0.509 (95% CI, 0.428-0.591). Sub-analysis including repeated hs-cTnI levels in a single individual, and early (<3 mo) EMB also showed no diagnostic utility of hs-cTnI measurement (area under the curve 0.512)., Conclusions: In the largest published study to date, we found no association between hs-cTnI concentration and the presence of significant ACR on surveillance EMB. Measurement of hs-cTnI may not be a useful technique for diagnosis or exclusion of ACR after heart transplantation., Competing Interests: K.K.L. has received an honorarium unrelated to this research from Abbotts Diagnostics and N.L.M. has received honorarium and grants unrelated to this research, from Abbots Diagnostics, Roche Diagnostics, and Siemens Healthcare. The other authors declare no conflicts of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
9. Coronary imaging of cardiac allograft vasculopathy predicts current and future deterioration of left ventricular function in patients with orthotopic heart transplantation.
- Author
-
Reddy SA, Khialani BV, Lambert B, Floré V, Brown AJ, Pettit SJ, West NE, Lewis C, Parameshwar J, Bhagra S, Kydd A, and Hoole SP
- Subjects
- Allografts, Coronary Angiography methods, Humans, Stroke Volume, Ultrasonography, Interventional, Ventricular Function, Left, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease etiology, Heart Diseases, Heart Transplantation adverse effects, Heart Transplantation methods
- Abstract
Background: Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) improve sensitivity of cardiac allograft vasculopathy (CAV) detection compared to invasive coronary angiography (ICA), but their ability to predict clinical events is unknown. We determined whether severe CAV detected with ICA, IVUS, or OCT correlates with graft function., Methods: Comparison of specific vessel parameters between IVUS and OCT on 20 patients attending for angiography 12-24 months post-orthotopic heart transplant. Serial left ventricular ejection fraction (EF) was recorded prospectively., Results: Analyzing 55 coronary arteries, OCT and IVUS correlated well for vessel CAV characteristics. A mean intimal thickness (MIT)
OCT > .25 mm had a sensitivity of 86.7% and specificity of 74.3% at detecting Stanford grade 4 CAV. Those with angiographically evident CAV had significant reduction in graft EF over 7.3 years follow-up (median ΔEF -2% vs +1.5%, P = .03). Patients with MITOCT > .25 mm in at least one vessel had a lower median EF at time of surveillance (57% vs 62%, P = .014). Two MACEs were noted., Conclusion: Imaging with OCT correlates well with IVUS for CAV detection. Combined angiography and OCT to screen for CAV within 12-24 months of transplant predicts concurrent and future deterioration in graft function., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)- Published
- 2022
- Full Text
- View/download PDF
10. Equity of Access to National Advanced Heart Failure Services.
- Author
-
Pettit SJ and Erhayiem B
- Subjects
- Health Services Accessibility, Humans, Registries, Heart Failure diagnosis, Heart Failure therapy, Heart-Assist Devices
- Published
- 2021
- Full Text
- View/download PDF
11. HeartMate 3: real-world performance matches pivotal trial.
- Author
-
Pettit SJ
- Subjects
- Humans, Registries, Heart Failure therapy, Heart-Assist Devices
- Published
- 2020
- Full Text
- View/download PDF
12. Low Pulmonary Artery Pulsatility Index Is Associated With Adverse Outcomes in Ambulatory Patients With Advanced Heart Failure.
- Author
-
Cesini S, Bhagra S, and Pettit SJ
- Subjects
- Humans, Male, Middle Aged, Pulmonary Artery diagnostic imaging, Pulmonary Wedge Pressure, Ventricular Function, Right, Heart Failure diagnostic imaging, Heart-Assist Devices, Ventricular Dysfunction, Right
- Abstract
Background: The pulmonary artery pulsatility index (PAPi) is a composite measure of right heart function, and low PAPi is associated with increased likelihood of mortality in patients hospitalized with cardiogenic shock. Our aim was to determine how PAPi correlates with other measures of right heart function and whether PAPi is associated with outcomes in ambulatory outpatients with advanced heart failure., Methods: We assessed 673 consecutive ambulatory outpatients for heart transplantation over 10 years. The median age was 52 years, 72% were male, and dilated cardiomyopathy was the most common cause. All patients underwent detailed assessment, including right heart catheterization, and PAPi was calculated. The coprimary endpoints were death, urgent heart transplantation and mechanical circulatory support., Results: Median PAPi was 2.2 (interquartile range 1.42-3.62), and variation was predominantly due to variation in right atrial pressure. PAPi was well correlated with the right atrial pressure to pulmonary capillary wedge pressure ratio (rho -0.766) but less well correlated with the right ventricular stroke work index (rho 0.561) and tricuspid annular plane systolic excursion (rho 0.292). Patients in the lowest PAPi quartile (0.16-1.41) had lower event-free survival at 1 year (68.7%) and 3 years (45.6%) compared with all other PAPi quartiles (log rank P = 0.0286)., Conclusions: PAPi offers a composite measure of right heart function that differs from other right heart catheter or echocardiographic measures. A PAPi of less than 1.41 is associated with adverse clinical outcomes in ambulatory outpatients with advanced heart failure., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
13. Transplantation of Hearts Donated After Circulatory-Determined Death.
- Author
-
Pettit SJ and Petrie MC
- Subjects
- Death, Heart, Humans, Perfusion, Heart Failure
- Published
- 2019
- Full Text
- View/download PDF
14. Improving anticoagulation of patients with an implantable left ventricular assist device.
- Author
-
Sage W, Gottiparthy A, Lincoln P, Tsui SSL, and Pettit SJ
- Abstract
Patients supported with implantable left ventricular assist devices (LVAD) have a significant risk of bleeding and thromboembolic complications. All patients require anticoagulation with warfarin, aiming for a target international normalised ratio (INR) of 2.5 and most patients also receive antiplatelet therapy. We found marked variation in the frequency of INR measurements and proportion of time outside the therapeutic INR range in our LVAD-supported patients. As part of a quality improvement initiative, home INR monitoring and a networked electronic database for recording INR results and treatment decisions were introduced. These changes were associated with increased frequency of INR measurement. We anticipate that changes introduced in this quality improvement project will reduce the likelihood of adverse events during long-term LVAD support., Competing Interests: Competing interests: None declared.
- Published
- 2018
- Full Text
- View/download PDF
15. Retained pacemaker and implantable cardioverter-defibrillator components after heart transplantation are common and may lead to adverse events.
- Author
-
Pettit SJ, Orzalkiewicz M, Nawaz MA, Lewis C, Parameshwar J, and Tsui S
- Subjects
- Adult, Databases, Factual, Device Removal, England, Female, Heart Failure diagnosis, Heart Failure physiopathology, Humans, Male, Middle Aged, Postoperative Complications diagnosis, Postoperative Complications surgery, Prosthesis Design, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Defibrillators, Implantable adverse effects, Heart Failure surgery, Heart Transplantation adverse effects, Heart Transplantation mortality, Pacemaker, Artificial adverse effects, Postoperative Complications etiology
- Abstract
Aims: Many patients have a cardiac implantable electronic device (CIED) extracted at the time of heart transplantation. CIED components may be retained after heart transplantation, but their frequency, nature, and clinical significance is uncertain., Methods and Results: Consecutive patients that underwent heart transplantation over 10 years from 1 January 2007 until 1 January 2017 were identified from the unit database. Pre- and post-operative chest radiographs were reviewed by two independent observers for the presence of CIED components. Adverse events relating to any retained CIED component were recorded. Two hundred and six patients had a CIED removed at the time of transplantation. Retained CIED components were present in 86 (42%) patients. The most common retained CIED components were suture sleeves and superior vena cava (SVC) coils of dual coil implantable cardioverter-defibrillator (ICD) leads. An SVC coil was retained in 25% of patients that had a dual coil ICD lead. Seven adverse events were associated with CIED removal or retained CIED components, including one fatal event. However, retained CIED components were not associated with reduced long-term survival after heart transplantation., Conclusion: Retained CIED components were seen in 42% of patients that had a CIED prior to transplantation, may be associated with serious adverse events but are not associated with reduced long-term survival. Cardiac surgeons should be aware of all CIED system components and be familiar with techniques for their complete removal at the time of transplantation.
- Published
- 2018
- Full Text
- View/download PDF
16. Utility of troponin assays for exclusion of acute cellular rejection after heart transplantation: A systematic review.
- Author
-
Fitzsimons S, Evans J, Parameshwar J, and Pettit SJ
- Subjects
- Humans, Graft Rejection blood, Graft Rejection diagnosis, Heart Transplantation, Troponin blood
- Abstract
Background: Acute cellular rejection (ACR) is a common complication in the first year after heart transplantation (HT). Routine surveillance for ACR is undertaken by endomyocardial biopsy (EMB). Measurement of cardiac troponins (cTn) in serum is an established diagnostic test of cardiac myocyte injury. This systematic review aimed to determine whether cTn measurement could be used to diagnose or exclude ACR., Methods: PubMed, Google Scholar and the JHLT archive were searched for studies reporting the result of a cTn assay and a paired surveillance EMB. Significant ACR was defined as International Society for Heart and Lung Transplantataion (ISHLT) Grade ≥3a/≥2R. Considerable heterogeneity between studies precluded quantitative meta-analysis. Individual study sensitivity and specificity data were examined and used to construct a pooled hierarchical summary receiver-operator characteristic (ROC) curve., Results: Twelve studies including 993 patients and 3,803 EMBs, of which 3,729 were paired with cTn levels, had adequate data available for inclusion. The overall rate of significant ACR was 12%. There was wide variation in diagnostic performance. cTn assays demonstrated sensitivity of 8% to 100% and specificity of 13% to 88% for detection of ACR. The positive predictive value (PPV) was low but the negative predictive value (NPV) was relatively high (79% to 100%). High-sensitivity cTn assays had greater sensitivity and NPV than conventional cTn assays for detection of ACR (sensitivity: 82% to 100% vs 8% to 77%; NPV: 97% to 100% vs 81% to 95%, respectively)., Conclusions: cTn assays do not have sufficient specificity to diagnose ACR in place of EMB. However, hs-cTn assays may have sufficient sensitivity and negative predictive value to exclude ACR and limit the need for surveillance EMB. Further research is required to assess this strategy., (Copyright © 2018 International Society for the Heart and Lung Transplantation. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
17. High-Sensitivity Cardiac Troponin and New-Onset Heart Failure: A Systematic Review and Meta-Analysis of 67,063 Patients With 4,165 Incident Heart Failure Events.
- Author
-
Evans JDW, Dobbin SJH, Pettit SJ, Di Angelantonio E, and Willeit P
- Subjects
- Aged, Biomarkers metabolism, Female, Heart Failure etiology, Humans, Male, Middle Aged, Myocardial Infarction complications, Heart Failure diagnosis, Myocardial Infarction diagnosis, Troponin metabolism
- Abstract
Objectives: The aim of this study was to systematically collate and appraise the available evidence regarding the association between high-sensitivity cardiac troponin (hs-cTn) and incident heart failure (HF) and the added value of hs-cTn in HF prediction., Background: Identification of subjects at high risk for HF and early risk factor modification with medications such as angiotensin-converting enzyme inhibitors may delay the onset of HF. Hs-cTn has been suggested as a prognostic marker for the incidence of first-ever HF in asymptomatic subjects., Methods: PubMed, Embase, and Web of Science were systematically searched for prospective cohort studies published before January 2017 that reported associations between hs-cTn and incident HF in subjects without baseline HF. Study-specific multivariate-adjusted hazard ratios (HRs) were pooled using random-effects meta-analysis., Results: Data were collated from 16 studies with a total of 67,063 subjects and 4,165 incident HF events. The average age was 57 years, and 47% were women. Study quality was high (Newcastle-Ottawa score 8.2 of 9). In a comparison of participants in the top third with those in the bottom third of baseline values of hs-cTn, the pooled multivariate-adjusted HR for incident HF was 2.09 (95% confidence interval [CI]: 1.76 to 2.48; p < 0.001). Between-study heterogeneity was high, with an I
2 value of 80%. HRs were similar in men and women (2.29 [95% CI: 1.64 to 3.21] vs. 2.18 [95% CI: 1.68 to 2.81]) and for hs-cTnI and hs-cTnT (2.09 [95% CI: 1.53 to 2.85] vs. 2.11 [95% CI: 1.69 to 2.63]) and across other study-level characteristics. Further adjustment for B-type natriuretic peptide yielded a similar HR of 2.08 (95% CI: 1.64 to 2.65). Assay of hs-cTn in addition to conventional risk factors provided improvements in the C index of 1% to 3%., Conclusions: Available prospective studies indicate a strong association of hs-cTn with the risk of first-ever HF and significant improvements in HF prediction., (Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
18. Intravascular ultrasound of the proximal left anterior descending artery is sufficient to detect early cardiac allograft vasculopathy.
- Author
-
Floré V, Brown AJ, Pettit SJ, West NEJ, Lewis C, Parameshwar J, and Hoole SP
- Subjects
- Adolescent, Adult, Aged, Allografts, Coronary Angiography, Coronary Vessels diagnostic imaging, Early Diagnosis, Endovascular Procedures, Female, Follow-Up Studies, Graft Rejection diagnostic imaging, Graft Rejection etiology, Graft Survival, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Risk Factors, Vascular Diseases diagnostic imaging, Vascular Diseases etiology, Young Adult, Coronary Vessels pathology, Graft Rejection diagnosis, Heart Transplantation adverse effects, Postoperative Complications, Ultrasonography methods, Vascular Diseases diagnosis
- Abstract
Objective: Cardiac allograft vasculopathy (CAV) can be detected early with intravascular ultrasound (IVUS), but there is limited information on the most efficient imaging protocol., Methods: Coronary angiography and IVUS of the three coronary arteries were performed. Volumetric IVUS analysis was performed, and a Stanford grade determined for each vessel., Results: Eighteen patients were included 18 (range 12-24) months after transplantation. Angiographic CAV severity ranged from none (CAV0) to mild (CAV1), whereas IVUS CAV severity ranged from none (Stanford grade I) to severe (grade IV). Maximal intimal thickness measured with IVUS was significantly greater in the LAD (0.84 ± 0.48 mm) than in the LCX (0.46 ± 0.32 mm) or the RCA (0.53 ± 0.41 mm, P = .005). Diagnostic accuracy of IVUS in the left anterior descending artery was 100% (18 of 18 Stanford grades matched the patient's highest overall Stanford grade), 66% in the right coronary artery (12 of 18), and 56% in the left circumflex artery (11 of 18). The minimal required length of left anterior descending artery pullbacks to attain 100% accuracy was 36 mm (range 3-36 mm) distal from the guide catheter ostium., Conclusions: These data suggest that focal IVUS imaging of the proximal LAD followed by volumetric analysis may suffice when screening for transplant vasculopathy., (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
19. Management of an acute catecholamine-induced cardiomyopathy and circulatory collapse: a multidisciplinary approach.
- Author
-
Casey RT, Challis BG, Pitfield D, Mahroof RM, Jamieson N, Bhagra CJ, Vuylsteke A, Pettit SJ, and Chatterjee KC
- Abstract
A phaeochromocytoma (PC) is a rare, catecholamine-secreting neuroendocrine tumour arising from the adrenal medulla. Presenting symptoms of this rare tumour are highly variable but life-threatening multiorgan dysfunction can occur secondary to catecholamine-induced hypertension or hypotension and subsequent cardiovascular collapse. High levels of circulating catecholamines can induce an acute stress cardiomyopathy, also known as Takotsubo cardiomyopathy. Recent studies have focused on early diagnosis and estimation of the prevalence of acute stress cardiomyopathy in patients with PC, but very little is reported about management of these complex cases. Here, we report the case of a 38-year-old lady who presented with an acute Takotsubo or stress cardiomyopathy and catecholamine crisis, caused by an occult left-sided 5 cm PC. The initial presenting crisis manifested with symptoms of severe headache and abdominal pain, triggered by a respiratory tract infection. On admission to hospital, the patient rapidly deteriorated, developing respiratory failure, cardiogenic shock and subsequent cardiovascular collapse due to further exacerbation of the catecholamine crisis caused by a combination of opiates and intravenous corticosteroid. An echocardiogram revealed left ventricular apical hypokinesia and ballooning, with an estimated left ventricular ejection fraction of 10-15%. Herein, we outline the early stabilisation period, preoperative optimisation and intraoperative management, providing anecdotal guidance for the management of this rare life-threatening complication of PC., Learning Points: A diagnosis of phaeochromocytoma should be considered in patients presenting with acute cardiomyopathy or cardiogenic shock without a clear ischaemic or valvular aetiology.Catecholamine crisis is a life-threatening medical emergency that requires cross-disciplinary expertise and management to ensure the best clinical outcome.After initial resuscitation, treatment of acute catecholamine-induced stress cardiomyopathy requires careful introduction of alpha-blockade followed by beta-blockade if necessary to manage β-receptor-mediated tachycardia.Prolonged α-adrenergic receptor stimulation by high levels of circulating catecholamines precipitates arterial vasoconstriction and intravascular volume contraction, which can further exacerbate hypotension. Invasive pressure monitoring can aid management of intravascular volume in these complex patients.
- Published
- 2017
- Full Text
- View/download PDF
20. Socioeconomic Deprivation and Survival After Heart Transplantation in England: An Analysis of the United Kingdom Transplant Registry.
- Author
-
Evans JD, Kaptoge S, Caleyachetty R, Di Angelantonio E, Lewis C, Parameshwar KJ, and Pettit SJ
- Subjects
- Adult, Age Factors, Comorbidity, England epidemiology, Female, Heart Failure diagnosis, Heart Failure economics, Heart Failure mortality, Heart Transplantation adverse effects, Heart Transplantation mortality, Humans, Linear Models, Logistic Models, Male, Middle Aged, Multivariate Analysis, Proportional Hazards Models, Registries, Risk Assessment, Risk Factors, Sex Factors, Time Factors, Tissue and Organ Procurement, Treatment Outcome, Health Status Disparities, Healthcare Disparities economics, Heart Failure surgery, Heart Transplantation economics, Poverty
- Abstract
Background: Socioeconomic deprivation (SED) is associated with shorter survival across a range of cardiovascular and noncardiovascular diseases. The association of SED with survival after heart transplantation in England, where there is universal healthcare provision, is unknown., Methods and Results: Long-term follow-up data were obtained for all patients in England who underwent heart transplantation between 1995 and 2014. We used the United Kingdom Index of Multiple Deprivation (UK IMD), a neighborhood level measure of SED, to estimate the relative degree of deprivation for each recipient. Cox proportional hazard models were used to examine the association between SED and overall survival and conditional survival (dependant on survival at 1 year after transplantation) during follow-up. Models were stratified by transplant center and adjusted for donor and recipient age and sex, ethnicity, serum creatinine, diabetes mellitus, and heart failure cause. A total of 2384 patients underwent heart transplantation. There were 1101 deaths during 17 040 patient-year follow-up. Median overall survival was 12.6 years, and conditional survival was 15.6 years. Comparing the most deprived with the least deprived quintile, adjusted hazard ratios for all-cause mortality were 1.27 (1.04-1.55; P =0.021) and 1.59 (1.22-2.09; P =0.001) in the overall and conditional models, respectively. Median overall survival and conditional survival were 3.4 years shorter in the most deprived quintile than in the least deprived., Conclusions: Higher SED is associated with shorter survival in heart transplant recipients in England and should be considered when comparing outcomes between centers. Future research should seek to identify modifiable mediators of this association., (© 2016 American Heart Association, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
21. Alemtuzumab as a novel treatment for refractory giant cell myocarditis after heart transplantation.
- Author
-
Evans JD, Pettit SJ, Goddard M, Lewis C, and Parameshwar JK
- Subjects
- Adult, Alemtuzumab, Giant Cells pathology, Humans, Male, Myocarditis etiology, Myocarditis pathology, Postoperative Complications, Recurrence, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Heart Transplantation, Myocarditis drug therapy
- Published
- 2016
- Full Text
- View/download PDF
22. Right ventricular failure due to late embolic RV infarction during continuous flow LVAD support.
- Author
-
Plymen C, Pettit SJ, Tsui S, and Lewis C
- Subjects
- Cardiomyopathy, Dilated physiopathology, Coronary Occlusion pathology, Coronary Vessels pathology, Follow-Up Studies, Heart Failure pathology, Heart Transplantation methods, Humans, Male, Middle Aged, Myocardial Ischemia pathology, Treatment Outcome, Ultrasonography, Ventricular Dysfunction, Right diagnostic imaging, Ventricular Dysfunction, Right physiopathology, Cardiomyopathy, Dilated surgery, Heart Failure physiopathology, Heart-Assist Devices, Myocardial Infarction physiopathology, Tachycardia, Ventricular physiopathology
- Abstract
This report describes a 63-year-old man with a dilated cardiomyopathy, who was supported with a continuous flow left ventricular assist device (LVAD), and on the waiting list for heart transplantation. After a long period of stability, he presented with recurrent ventricular tachycardia and rapidly developed progressive right ventricular (RV) failure. He required implantation of a temporary RV assist device to regain stability and subsequently underwent urgent heart transplantation. The explanted heart showed multiple areas of ischaemic damage to the RV myocardium, but there was no significant underlying coronary artery disease. It appears that the ventricular arrhythmias and subsequent RV failure were due to an embolic event in the territory of the right coronary artery. The case highlights that coronary embolism is a rare cause of RV failure during LVAD support and demonstrates the utility of temporary RV assist device support as a bridge to heart transplantation., (2015 BMJ Publishing Group Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
23. Heart transplantation for advanced heart failure due to cardiac sarcoidosis.
- Author
-
Theofilogiannakos EK, Pettit SJ, Ghazi A, Rassl D, Lewis C, and Parameshwar J
- Subjects
- Adult, Cardiomyopathies complications, Cardiomyopathies diagnosis, Cardiomyopathies mortality, Case-Control Studies, England, Female, Heart Failure diagnosis, Heart Failure etiology, Heart Failure mortality, Heart Transplantation adverse effects, Heart Transplantation mortality, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Recurrence, Risk Factors, Sarcoidosis complications, Sarcoidosis diagnosis, Sarcoidosis mortality, Time Factors, Treatment Outcome, Cardiomyopathies surgery, Heart Failure surgery, Sarcoidosis surgery
- Abstract
Background: Selected patients with cardiac sarcoidosis undergo heart transplantation, but outcomes may be adversely affected by recurrent cardiac sarcoidosis or progressive extra-cardiac sarcoidosis., Objectives: We present our single-center experience of patients with cardiac sarcoidosis who underwent heart transplantation., Methods: Consecutive patients that underwent heart transplantation between 1990 and 2012 were assessed. Cardiac sarcoidosis was defined by the presence of multiple non-caseating epithelioid cell granulomata in the explanted heart. Baseline characteristics and clinical outcomes were compared with a control group without cardiac sarcoidosis that underwent heart transplantation during this period., Results: 901 patients underwent heart transplantation during the study period, of whom 4 patients had a pre-transplant diagnosis of cardiac sarcoidosis and 8 patients had sarcoidosis identified in the explanted heart. Patients with cardiac sarcoidosis had excellent post-transplant outcomes with survival of 92% at one year and 83% at five years. Survival was similar to patients that underwent heart transplantation for an alternate diagnosis. We did not encounter recurrent cardiac sarcoidosis or progressive extra-cardiac sarcoidosis during 1001 months of follow-up., Conclusions: Carefully selected patients with advanced heart failure due to cardiac sarcoidosis have an acceptable outcome after transplantation. Cardiologists should be aware that reported experience of transplantation for cardiac sarcoidosis mostly represents isolated cardiac sarcoidosis that was only diagnosed at pathological examination of the explanted heart.
- Published
- 2015
24. Percutaneous withdrawal of HeartWare HVAD left ventricular assist device support.
- Author
-
Pettit SJ, Shapiro LM, Lewis C, Parameshwar JK, and Tsui SS
- Subjects
- Adolescent, Heart Failure physiopathology, Humans, Male, Heart Failure therapy, Heart-Assist Devices, Recovery of Function physiology, Ventricular Function, Left physiology
- Published
- 2015
- Full Text
- View/download PDF
25. The management of patients with aortic regurgitation and severe left ventricular dysfunction: a systematic review.
- Author
-
Badar AA, Brunton AP, Mahmood AH, Dobbin S, Pozzi A, McMinn JF, Sinclair AJ, Gardner RS, Petrie MC, Curry PA, Al-Attar NH, and Pettit SJ
- Subjects
- Aortic Valve Insufficiency complications, Humans, Retrospective Studies, Ventricular Dysfunction, Left complications, Aortic Valve Insufficiency therapy, Ventricular Dysfunction, Left therapy
- Abstract
A systematic search of Medline, EMBASE and CINAHL electronic databases was performed. Original research articles reporting all-cause mortality following surgery in patients with aortic regurgitation and severe left ventricular systolic dysfunction (LVSD) were identified. Nine of the 10 eligible studies were observational, single-center, retrospective analyses. Survival ranged from 86 to 100% at 30 days; 81 to 100% at 1 year and 68 to 84% at 5 years. Three studies described an improvement in mean left ventricular ejection fraction (LVEF) following aortic valve replacement (AVR) of 5-14%; a fourth study reported an increase in mean left ventricular ejection fraction (LVEF) of 9% in patients undergoing isolated AVR but not when AVR was combined with coronary artery bypass graft and/or mitral valve surgery. Three studies demonstrated improvements in functional New York Heart Association (NYHA) class following AVR. Additional studies are needed to clarify the benefits of AVR in patients with more extreme degrees of left ventricular systolic dysfunction (LVSD) and the potential roles of cardiac transplantation and transaortic valve implantation.
- Published
- 2015
- Full Text
- View/download PDF
26. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation?
- Author
-
Randles DA, Hawkins NM, Shaw M, Patwala AY, Pettit SJ, and Wright DJ
- Subjects
- Aged, Aged, 80 and over, Death, Sudden, Cardiac etiology, Female, Humans, Male, Middle Aged, Observer Variation, Practice Guidelines as Topic, Predictive Value of Tests, Primary Prevention methods, Prosthesis Implantation methods, Reproducibility of Results, Risk Assessment, Risk Factors, Secondary Prevention methods, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Electric Countershock instrumentation, Electrocardiography, Eligibility Determination, Patient Selection, Primary Prevention instrumentation, Prosthesis Implantation instrumentation, Secondary Prevention instrumentation
- Abstract
Aims: To determine the number of patients with a primary or secondary prevention implantable cardioverter-defibrillator (ICD) indication who are eligible for subcutaneous ICD (S-ICD) implantation according to the S-ICD manufacturer's surface electrocardiogram (ECG) screening template., Methods and Results: One hundred and ninety-six ICD patients with a non-paced ventricle were assessed using erect and supine ECG limb lead recordings to simulate the three S-ICD sensing vectors. Each ECG lead was scrutinized by two independent observers. Subcutaneous ICD eligibility required two or more leads to satisfy the S-ICD screening template in both erect and supine positions. Overall, 85.2% of patients [95% confidence interval (CI): 80.2-90.2%] fulfilled surface ECG screening criteria. The proportion of patients with 3, 2, 1, and 0 qualifying leads were 37.2% (95% CI: 30.4-44.0%), 48.0% (95% CI: 41.0-55.0%), 11.2% (95% CI: 6.8-15.6%), and 3.6% (95% CI: 1.0-6.2%). The S-ICD screening template was satisfied more often by Lead III (primary vector, 83.7%, 95% CI: 78.5-88.9%) and Lead II (secondary vector, 82.7%, 95% CI: 77.4-88.0%) compared with Lead I (alternate vector, 52.6%, 95% CI: 45.6-59.6%). A prolonged QRS duration was the only baseline characteristic independently associated with ineligibility for S-ICD implantation. There was 92.9% agreement between the two independent observers in assessment of eligibility using the S-ICD screening template., Conclusion: About 85.2% of patients with an indication for a primary or secondary prevention ICD have a surface ECG that is suitable for S-ICD implantation when assessed with an S-ICD screening template. There is minor inter-observer variation in assessment of eligibility using the S-ICD screening template., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com.)
- Published
- 2014
- Full Text
- View/download PDF
27. Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy.
- Author
-
Lang NN, Badar AA, Pettit SJ, Templeton S, Connelly DT, and Gardner RS
- Subjects
- Aged, Cardiac Resynchronization Therapy Devices, Echocardiography, Female, Heart Failure diagnostic imaging, Humans, Male, Middle Aged, Retrospective Studies, Cardiac Resynchronization Therapy, Heart Failure blood, Heart Failure physiopathology, Heart Failure therapy, Natriuretic Peptide, Brain blood, Peptide Fragments blood
- Abstract
Aims: Effective cardiac resynchronization therapy may depend upon the distance between left ventricular (LV) and right ventricular (RV) pacing leads. We assessed the influence of lead separation upon circulating NT-proBNP., Materials & Methods: In total, 132 patients underwent assessment, including NT-proBNP assay, before and after cardiac resynchronization therapy. 3D lead separation was calculated from postero-anterior and lateral chest radiography., Results: Lead separation correlated with NT-proBNP reduction (r = 0.25; p = 0.004). Circulating NT-proBNP only fell in those with lead separation in the upper two quartiles. Deteriorating NT-proBNP occurred in 44 patients. Lead separation was less in these patients compared with those with an improvement (corrected 3D lead separation: 148.0 ± 5.38 and 170.5 ± 4.21 mm, respectively; p = 0.0018)., Conclusion: Left ventricular-right ventricular lead separation correlates with postcardiac resynchronization therapy improvements in circulating NT-proBNP, a powerful marker of heart failure status and prognosis. Attention should be paid to achieving maximal lead separation at implantation.
- Published
- 2014
- Full Text
- View/download PDF
28. Clinical experience of subcutaneous and transvenous implantable cardioverter defibrillators in children and teenagers.
- Author
-
Pettit SJ, McLean A, Colquhoun I, Connelly D, and McLeod K
- Subjects
- Adolescent, Child, Child, Preschool, Female, Heart Failure diagnosis, Humans, Longitudinal Studies, Male, Risk Assessment, Scotland, Survival, Treatment Outcome, Arrhythmias, Cardiac etiology, Arrhythmias, Cardiac prevention & control, Defibrillators, Implantable adverse effects, Defibrillators, Implantable classification, Heart Failure prevention & control
- Abstract
Background: Subcutaneous implantable cardioverter defibrillator (S-ICD) systems have no components in contact with the heart and may avoid complications such as lead fracture, venous obstruction, or endocarditis that occur with transvenous leads. Concerns have been raised regarding inappropriate shocks and pocket erosion with S-ICD systems. We have compared the performance of S-ICD and transvenous ICD systems in children and teenagers., Methods: We studied consecutive patients <20 years of age who received an ICD over a 4-year period in two Scottish centers. Baseline characteristics, complications, and ICD therapy were recorded. The primary outcome measure was survival. The secondary outcome measure was survival-free from inappropriate ICD therapy or system revision., Results: Nine S-ICD were implanted in nine patients. Eight transvenous ICD were implanted in six patients; two were redo procedures. Baseline characteristics were well matched. Median duration of follow-up was lower for S-ICD (20 months) than for transvenous ICD (36 months, P = 0.0262). Survival was 100% in both groups. Survival free of inappropriate therapy or system revision was 89% for S-ICD and 25% for transvenous ICD systems (log-rank test, P = 0.0237). No S-ICD were extracted, but three transvenous ICD were extracted due to infection (n = 1) and lead failure (n = 2)., Conclusions: In real-world use in children and teenagers, S-ICD may offer similar survival benefit to transvenous ICD, with a lower incidence of complications requiring reoperation. In the absence of randomized trials, S-ICD should be compared prospectively with transvenous ICD in large multicenter registries with comparable periods of follow-up., (©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
29. Pseudo-pseudo confusion.
- Author
-
Pettit SJ, Wright DJ, Currie P, and Modi S
- Subjects
- Arrhythmias, Cardiac classification, Diagnosis, Differential, Humans, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac prevention & control, Artifacts, Cardiac Resynchronization Therapy Devices, Diagnostic Errors prevention & control, Electrocardiography methods
- Published
- 2013
- Full Text
- View/download PDF
30. Deactivation of implantable cardioverter-defibrillators at end of life.
- Author
-
Pettit SJ, Jackson CE, and Gardner RS
- Subjects
- Humans, Terminal Care methods, Attitude of Health Personnel, Attitude to Health, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Terminal Care ethics
- Abstract
It is inevitable that all patients with implantable cardioverter-defibrillators (ICDs) will die during extended follow-up. End-of-life care planning may become appropriate as a patient's condition deteriorates. There is concern about multiple futile shocks in the final hours of life, although the incidence of this problem has been estimated at only 8-16%. Despite broad consensus that ICD deactivation should be discussed as part of end-of-life care planning, the effect of ICD deactivation, in particular whether life expectancy is altered, is uncertain. Many clinicians are reluctant to discuss ICD deactivation. Many patients have misconceptions regarding ICD function and value longevity above quality of life. As such, ICD deactivation is often discussed late or not at all. The management of ICDs in patients approaching death is likely to become a major problem in the coming years. This article will discuss directions in which clinical practice might develop and areas for future research.
- Published
- 2013
- Full Text
- View/download PDF
31. Remodeling in heart failure: from the left ventricle to service delivery.
- Author
-
Japp AG and Pettit SJ
- Subjects
- Evidence-Based Medicine, Heart Failure physiopathology, Humans, Ventricular Dysfunction, Left physiopathology, Heart Failure therapy, Ventricular Dysfunction, Left therapy, Ventricular Remodeling
- Abstract
Over the past three decades, advances in our understanding of heart failure pathophysiology have spurred the development of effective therapies for patients with heart failure and led to improved clinical outcomes. Further progress now requires increased provision of existing evidence-based therapies together with continued exploration of underlying pathogenic mechanisms and therapeutic targets. This was reflected at the 2012 Annual Autumn Meeting of the British Society for Heart Failure, attended by over 500 delegates from around the world with strong representation from all heart failure disciplines. The conference included a dedicated session on 'cardiac remodeling in left ventricular systolic dysfunction' as well as presentations on the latest evidence-based therapies in heart failure and aspects of service delivery within the UK.
- Published
- 2013
- Full Text
- View/download PDF
32. Standalone balloon aortic valvuloplasty: indications and outcomes from the UK in the transcatheter valve era.
- Author
-
Khawaja MZ, Sohal M, Valli H, Dworakowski R, Pettit SJ, Roy D, Newton J, Schneider H, Manoharan G, Doshi S, Muir D, Roberts D, Nolan J, Gunning M, Densem C, Spence MS, Chowdhary S, Mahadevan VS, Brecker SJ, Maccarthy P, Mullen M, Stables RH, Prendergast BD, de Belder A, Thomas M, Redwood S, and Hildick-Smith D
- Subjects
- Aged, Aged, 80 and over, Aortic Valve pathology, Aortic Valve physiopathology, Aortic Valve Stenosis diagnosis, Aortic Valve Stenosis mortality, Aortic Valve Stenosis physiopathology, Calcinosis diagnosis, Calcinosis mortality, Calcinosis physiopathology, Chi-Square Distribution, Female, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation mortality, Hemodynamics, Humans, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Multivariate Analysis, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Risk Factors, Treatment Outcome, United Kingdom, Aortic Valve Stenosis therapy, Balloon Valvuloplasty adverse effects, Balloon Valvuloplasty mortality, Calcinosis therapy, Cardiac Catheterization adverse effects, Cardiac Catheterization mortality, Heart Valve Prosthesis Implantation methods
- Abstract
Objectives: We sought to characterize UK-wide balloon aortic valvuloplasty (BAV) experience in the TAVI era., Background: BAV for acquired calcific aortic stenosis is in a phase of renaissance, largely due to the development of transcatheter aortic valve implantation (TAVI)., Methods: Data from 423 patients at 14 centers across the UK were analyzed., Results: Patients were aged 80.9 ± 9.5 years; 52.5% were male. Mean logistic EuroScore was 27.3% ± 16.8%. Mean peak transaortic gradient fell from 62.0 ± 26.3 to 28.3 ± 16.2 mm Hg. Aortic valve area increased from 0.58 ± 0.19 to 0.80 ± 0.25 cm(2) echocardiographically. Procedural complication rate was 6.3%, comprising death (2.4%), blood transfusion ≥ 2 U (1.2%), cardiac tamponade (1.0%), stroke (1.0%), vascular surgical repair (1.0%), coronary embolism (0.5%), and permanent pacemaker (0.2%). Mortality was 13.8% at 30 days and 36.3% at 12 months. Subsequently, 18.3% of patients underwent TAVI and 7.0% sAVR, with improved survival compared to those who had no further intervention (logrank < 0.0001). Multivariate Cox proportional hazard analysis demonstrated that survival was adversely effected by the presence of coronary artery disease (HR 1.53, 95%CI 1.08-2.17, P = 0.018), poor LV function (HR 1.54, 95%CI 1.09-2.16, P = 0.014), and either urgent (HR 1.70, 95%CI 1.18-2.45; P = 0.004) or emergent presentation (HR 3.72, 95%CI 2.27-6.08; P < 0.0001)., Conclusion: Balloon aortic valvuloplasty offers good immediate hemodynamic efficacy at an acceptable risk of major complications. Medium-term prognosis is poor in the absence of definitive therapy., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
33. The hazards of brussels sprouts consumption at Christmas.
- Author
-
Pettit SJ, Japp AG, and Gardner RS
- Subjects
- Anticoagulants administration & dosage, Humans, Male, Warfarin administration & dosage, Anticoagulants antagonists & inhibitors, Blood Coagulation Disorders drug therapy, Brassica adverse effects, Warfarin antagonists & inhibitors
- Published
- 2012
- Full Text
- View/download PDF
34. How small is too small? A systematic review of center volume and outcome after cardiac transplantation.
- Author
-
Pettit SJ, Jhund PS, Hawkins NM, Gardner RS, Haj-Yahia S, McMurray JJ, and Petrie MC
- Subjects
- Humans, Logistic Models, Multivariate Analysis, Odds Ratio, Quality Indicators, Health Care statistics & numerical data, Risk Assessment, Risk Factors, Survival Analysis, Time Factors, Treatment Outcome, Heart Transplantation adverse effects, Heart Transplantation mortality, Hospitals, High-Volume statistics & numerical data, Hospitals, Low-Volume statistics & numerical data, Outcome and Process Assessment, Health Care statistics & numerical data
- Abstract
Background: The aim of this study was to assess the relationship between the volume of cardiac transplantation procedures performed in a center and the outcome after cardiac transplantation., Methods and Results: PubMed, Embase, and the Cochrane library were searched for articles on the volume-outcome relationship in cardiac transplantation. Ten studies were identified, and all adopted a different approach to data analysis and varied in adjustment for baseline characteristics. The number of patients in each study ranged from 798 to 14401, and observed 1-year mortality ranged from 12.6% to 34%. There was no association between the continuous variables of center volume and observed mortality. There was a weak association between the continuous variables of center volume and adjusted mortality up to 1 year and a stronger association at 5 years. When centers were grouped in volume categories, low-volume centers had the highest adjusted mortality, intermediate-volume centers had lower adjusted mortality, and high-volume centers had the lowest adjusted mortality but were not significantly better than intermediate-volume centers. Category limits were arbitrary and varied between studies., Conclusions: There is a relationship between center volume and mortality in heart transplantation. The existence of a minimum acceptable center volume or threshold is unproven. However, a level of 10 to 12 heart transplants per year corresponds to the upper limit of low-volume categories that may have relatively higher mortality. It is not known whether outcomes for patients treated in low-volume transplant centers would be improved by reorganizing centers to ensure volumes in excess of 10 to 12 heart transplants per year.
- Published
- 2012
- Full Text
- View/download PDF
35. Use of implantable cardioverter defibrillators in patients with left ventricular assist devices.
- Author
-
Pettit SJ, Petrie MC, Connelly DT, Japp AG, Payne JR, Haj-Yahia S, and Gardner RS
- Subjects
- Humans, Risk Assessment methods, Tachycardia, Ventricular therapy, Ventricular Fibrillation therapy, Defibrillators, Implantable adverse effects, Heart-Assist Devices adverse effects, Stroke Volume, Tachycardia, Ventricular pathology, Ventricular Fibrillation pathology, Ventricular Function, Left
- Abstract
Patients with left ventricular assist devices (LVADs) are at high risk of sustained ventricular arrhythmias, but these may be remarkably well tolerated and the association with sudden death is unclear. Many patients who receive an LVAD already have an implantable cardioverter defibrillator (ICD). While it is standard practice to reactivate a previously implanted ICD in an LVAD recipient, this should include discussion of the revised risks and benefits of ICD therapy following LVAD implantation. In particular, patients should be warned that they might receive a significant number of ICD shocks that may not be life saving. When ICDs are reactivated, device programming should minimize the risk of repeated shocks for non-sustained or well-tolerated ventricular arrhythmias. Implantation of a primary prevention ICD after implantation of an LVAD is not supported by current evidence, poses potential risks, and should be the subject of a clinical trial before it becomes standard practice.
- Published
- 2012
- Full Text
- View/download PDF
36. ICDs in end-stage heart failure.
- Author
-
Pettit SJ, Browne S, Hogg KJ, Connelly DT, Gardner RS, May CR, Macleod U, and Mair FS
- Subjects
- Humans, Interprofessional Relations, Palliative Care, Patients, Terminal Care, Withholding Treatment ethics, Defibrillators, Implantable ethics, Heart Failure therapy
- Abstract
Implantable cardioverter defibrillators (ICDs) reduce mortality in selected patients with chronic heart failure but prognostic benefit is likely to attenuate with progression to end-stage heart failure. The incidence of multiple futile ICD shocks before death is uncertain. Only individual patients, supported by their healthcare professionals, can decide when ICD therapy becomes futile in end-stage heart failure. Despite consensus that ICD deactivation should be routinely discussed, this rarely occurs in clinical practice for many reasons including uncertainty about when to initiate these discussions and reluctance to confront death and dying. Patient and carer opinions about end-stage heart failure and ICD deactivation may not meet professional expectations. Future research should focus on these opinions and examine interventions that bridge the gap between best practice and the reality of current clinical practice.
- Published
- 2012
- Full Text
- View/download PDF
37. Cardiovascular manifestations of Alkaptonuria.
- Author
-
Pettit SJ, Fisher M, Gallagher JA, and Ranganath LR
- Subjects
- Adult, Age Distribution, Aged, Aortic Valve pathology, Aortic Valve Stenosis diagnosis, Causality, Cohort Studies, Comorbidity, Coronary Artery Disease diagnosis, Echocardiography methods, Female, Heart Valve Diseases diagnosis, Humans, Male, Middle Aged, Alkaptonuria epidemiology, Aortic Valve diagnostic imaging, Aortic Valve Stenosis epidemiology, Coronary Artery Disease epidemiology, Heart Valve Diseases epidemiology
- Abstract
The cardiovascular manifestations of alkaptonuria relate to deposition of ochronotic pigment within heart valves, endocardium, aortic intima and coronary arteries. We assessed 16 individuals with alkaptonuria for cardiovascular disease, including full electrocardiographic and echocardiographic assessment. The self reported prevalence of valvular heart disease and coronary artery disease was low. There was a significant burden of previously undiagnosed aortic valve disease, reaching a prevalence of over 40% by the fifth decade of life. The aortic valve disease was found to increase in both prevalence and severity with advancing age. In contrast to previous reports, we did not find a significant burden of mitral valve disease or coronary artery disease. These findings are important for the clinical follow-up of patients with alkaptonuria and suggest a role for echocardiographic surveillance of patients above 40 years old.
- Published
- 2011
- Full Text
- View/download PDF
38. Survey of infection in patients receiving antibody replacement treatment for immune deficiency.
- Author
-
Pettit SJ, Bourne H, and Spickett GP
- Subjects
- Adolescent, Adult, Aged, Female, Health Surveys, Humans, Immunoglobulin G blood, Immunoglobulins therapeutic use, Immunologic Deficiency Syndromes immunology, Immunologic Deficiency Syndromes therapy, Linear Models, Male, Middle Aged, Opportunistic Infections drug therapy, Opportunistic Infections immunology, Respiratory Tract Infections drug therapy, Respiratory Tract Infections immunology, Retrospective Studies, Immunologic Deficiency Syndromes complications, Opportunistic Infections complications, Respiratory Tract Infections complications
- Abstract
Background: Primary antibody deficiency disorders are a heterogeneous group of disorders, which are treated by regular infusions of immunoglobulin. Despite replacement treatment, patients remain susceptible to infection. Effective management of infections is necessary to prevent the complications of chronic infection., Aims: This retrospective survey of clinical practice examined the management of infections in patients who receive immunoglobulin replacement for immune deficiency., Methods: Patients who received immunoglobulin replacement treatment in Newcastle during the year 2000 were identified. Medical records were reviewed. Basic clinical information and details of immunoglobulin replacement treatment were recorded. Episodes of infection were defined by documented symptoms, signs, or investigation results, and by the prescription of an antibiotic course. Details of episodes of infection and antimicrobial treatment were recorded., Results: Thirty seven patients received immunoglobulin replacement during 2000. There were 101 episodes of infection. There was no correlation between the frequency of infection and the IgG trough value. Respiratory tract infections were most common (71 of 101). Where documented, 80% of infections were associated with clinical signs, 21% with pyrexia, and 64% with a raised C reactive protein value. Microbiological culture was performed in 30% of infections. Antimicrobial treatment was instituted along "best guess" lines in 99 of 101 episodes of infection., Conclusions: Management of respiratory tract infections represents the largest problem in antibody deficient patients. Greater use of microbiological culture might allow more effective prescription of antimicrobial treatment. The generation of treatment guidelines and improved communication with general practitioners could improve the management of all episodes of infection.
- Published
- 2002
- Full Text
- View/download PDF
39. Evaluation of dendritic cell immunogenicity after activation and chemical fixation: a mixed lymphocyte reaction model.
- Author
-
Pettit SJ, Neal DE, and Kirby JA
- Subjects
- Acetylmuramyl-Alanyl-Isoglutamine pharmacology, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes immunology, Cell Differentiation drug effects, Dendritic Cells cytology, Dendritic Cells drug effects, Dendritic Cells radiation effects, Fixatives, Gamma Rays, Humans, Immunotherapy, In Vitro Techniques, Interleukin-1 pharmacology, Lymphocyte Activation drug effects, Lymphocyte Culture Test, Mixed, Mycobacterium bovis immunology, Oligodeoxyribonucleotides pharmacology, Dendritic Cells immunology, Models, Immunological
- Abstract
Dendritic cells (DC) are central to the control of adaptive immunity. Their ability to activate antigen-specific T cells depends on their maturation state. Many microbial and inflammatory products have stimulated DC maturation. This in vitro study used assays of phenotype and function to examine the potential of bacillus Calmette-Guerin, muramyl dipeptide, and CpG-rich oligodeoxynucleotides to stimulate DC maturation. A chemical fixation method was developed to reliably assess the functional potential of stimulated DC within a mixed lymphocyte reaction model. Using this method, it was shown that bacillus Calmette-Guerin provides a maturation signal as effective as the prototype DC stimulant interleukin-1beta. Furthermore, weaker stimuli such as muramyl dipeptide and CpG-rich oligodeoxynucleotides also are able to induce functional maturation of DC. Using chemical fixation, it was possible to generate stable DC in an immature or a mature state. These observations have importance for our understanding of the regulation of adaptive immunity and for the design of DC-based immunotherapeutic strategies.
- Published
- 2002
- Full Text
- View/download PDF
40. Regulation of T-cell apoptosis: a mixed lymphocyte reaction model.
- Author
-
O'Flaherty E, Wong WK, Pettit SJ, Seymour K, Ali S, and Kirby JA
- Subjects
- Adult, Blotting, Western, Caspases metabolism, Cell Culture Techniques, Fas Ligand Protein, Flow Cytometry, Humans, Lymphocyte Activation immunology, Lymphocyte Culture Test, Mixed, Membrane Glycoproteins metabolism, Proto-Oncogene Proteins c-bcl-2 metabolism, fas Receptor immunology, Apoptosis immunology, T-Lymphocytes immunology
- Abstract
Despite the capacity for antigen-specific activation and rapid clonal expansion, homeostatic mechanisms ensure that the mature immune system contains a relatively stable number of T cells. In recent years, it has become apparent that this stability is a consequence of apoptotic death of most of the specific T cells generated during an immune response. Clearly this process must be tightly regulated in order to retain sufficient T-cell progeny to mediate an effective response, whilst allowing the rapid deletion of these cells at the end of the response to prevent lymphadenopathy and cross-reactive autoimmunity. In this study, the factors that regulate the sensitivity of T cells to apoptosis were investigated in vitro after the induction of primary T-cell activation within a mixed lymphocyte reaction (MLR). It was found that activated T cells rapidly acquire the expression of both Fas and Fas ligand (FasL) on their surface and contain high levels of the precursor form of the pro-apoptotic enzyme, caspase 8 (FLICE). However, these T cells were resistant for up to 5 days to apoptosis following the stimulation of Fas; a maximal apoptotic response was observed after 7 days. This time point coincided with a marked reduction in expression of the FLICE inhibitory protein (FLIP) and maximal activity of caspase 8. At time points beyond day 7, the number of viable cells in the MLR decreased further despite a reduction in the expression of FasL. However, the expression of interleukin-2 (IL-2) at these late time points was low, resulting in a decrease in expression of the anti-apoptotic protein Bcl-2. This can produce apoptosis by allowing leakage of cytochrome-c from mitochondria resulting in direct activation of the caspase cascade. In this study, it is shown that T cells are resistant to apoptosis for the first 5 days after activation as a consequence of insensitivity of the Fas pathway and the presence of intracellular Bcl-2. After between 5 and 7 days, the cells become sensitive to Fas-mediated apoptosis while retaining Bcl-2 expression. At later time points, Fas ligation is reduced but the cells respond to a decreased availability of IL-2 by reducing Bcl-2 expression; this encourages further apoptosis by allowing the direct activation of caspase enzymes.
- Published
- 2000
- Full Text
- View/download PDF
41. Immune selection in neoplasia: towards a microevolutionary model of cancer development.
- Author
-
Pettit SJ, Seymour K, O'Flaherty E, and Kirby JA
- Subjects
- Adaptation, Physiological, Clonal Anergy, Humans, Immunotherapy, Models, Immunological, Neoplasms genetics, Neoplasms therapy, Neoplasms immunology, Tumor Escape
- Abstract
The dual properties of genetic instability and clonal expansion allow the development of a tumour to occur in a microevolutionary fashion. A broad range of pressures are exerted upon a tumour during neoplastic development. Such pressures are responsible for the selection of adaptations which provide a growth or survival advantage to the tumour. The nature of such selective pressures is implied in the phenotype of tumours that have undergone selection. We have reviewed a range of immunologically relevant adaptations that are frequently exhibited by common tumours. Many of these have the potential to function as mechanisms of immune response evasion by the tumour. Thus, such adaptations provide evidence for both the existence of immune surveillance, and the concept of immune selection in neoplastic development. This line of reasoning is supported by experimental evidence from murine models of immune involvement in neoplastic development. The process of immune selection has serious implications for the development of clinical immunotherapeutic strategies and our understanding of current in vivo models of tumour immunotherapy.
- Published
- 2000
- Full Text
- View/download PDF
42. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.
- Author
-
Pettit SJ, Ali S, O'Flaherty E, Griffiths TR, Neal DE, and Kirby JA
- Subjects
- Antigens, CD genetics, B7-1 Antigen genetics, B7-2 Antigen, Cell Adhesion Molecules immunology, Histocompatibility Antigens Class I immunology, Histocompatibility Antigens Class II immunology, Humans, Membrane Glycoproteins genetics, Recombinant Proteins immunology, Antigens, CD immunology, B7-1 Antigen immunology, CD4-Positive T-Lymphocytes immunology, Lymphocyte Activation, Membrane Glycoproteins immunology, Urinary Bladder Neoplasms immunology
- Abstract
Transitional cell carcinomas (TCC) of the urinary bladder are known to express proteins which can yield potentially immunogenic peptide epitopes for expression in the context of cell surface class I or class II MHC antigens. However, additional costimulatory ligands must also be expressed before such a cell might directly induce full activation and proliferation of resting, antigen-specific T lymphocytes. Intravesical therapy might be used to manipulate T cell costimulation in order to promote specific rejection of TCC cells. This in vitro study examined the potential of such a strategy by transfection of the prototypical TCC line J82 with the important costimulatory molecules CD80 (B7-1) and CD86 (B7-2). Untransfected J82 cells expressed class I and II MHC antigens, a range of cell adhesion molecules, though did not induce T cell proliferation in a robust, allogeneic co-culture system. Transfected J82 cells expressed CD80 or CD86 at levels comparable to an antigen-presenting B cell line. Furthermore, functional surface expression of CD80 and CD86 was demonstrated in a mitogen-dependent assay of costimulation. However, neither CD80+ nor CD86+ transfectant J82 cells could induce significant proliferation of antigen-specific CD4+ T cells. Further analysis showed that bystander J82 cells could inhibit independent T cell activation in an effect dependent on direct cell contact. This inhibitory effect was associated with increased cell death in the responding lymphocyte population and is concordant with surface expression of CD95L by the J82 cell line.
- Published
- 1999
- Full Text
- View/download PDF
43. Examination of the sensitivity of T cells to Fas ligation: induction of allospecific apoptosis.
- Author
-
O'Flaherty E, Ali S, Pettit SJ, and Kirby JA
- Subjects
- Antibodies immunology, Apoptosis immunology, DNA Fragmentation physiology, Drug Resistance immunology, Epitopes, Fas Ligand Protein, Humans, In Situ Nick-End Labeling, Interleukin-2 metabolism, Isoantigens immunology, Lymphocyte Activation physiology, Lymphocyte Culture Test, Mixed, Proto-Oncogene Proteins c-bcl-2 metabolism, T-Lymphocytes immunology, Time Factors, Tumor Cells, Cultured, fas Receptor immunology, Membrane Glycoproteins pharmacology, T-Lymphocytes drug effects, T-Lymphocytes physiology
- Abstract
Background: Alloantigen-reactive T cells represent the major barrier to successful organ transplantation. However, it has been shown that cotransplantation of Fas ligand (FasL)-expressing cells can induce functional allograft tolerance in some model systems. In this study, the basis for this tolerance was investigated using a sensitive in vitro assay system., Methods: T lymphocytes were activated by coculture with an allogeneic Epstein Barr virus-transformed B-cell line. Samples of the lymphocytes were taken daily and treated with agonistic anti-Fas antibodies or FasL-expressing cells. The time in culture required for development of optimal sensitivity to Fas-mediated apoptosis was assessed by Tdt-mediated nick end labeling (TUNEL) staining and the JAM assay of DNA fragmentation. After the induction of optimal apoptosis, a series of experiments was performed to assess the response of the T-cell population to antigen-specific rechallenge., Results: Treatment of the allospecific lymphocyte population with anti-Fas antibodies or Fas-L-expressing cells did not induce apoptosis efficiently until between 6 and 7 days after initiation of the mixed lymphocyte culture; this time corresponded with decreases in the ambient interleukin 2 concentration and in Bcl-2 expression. In addition, induction of apoptosis by treatment with the agonistic anti-Fas antibody reduced the lymphoproliferative response of the T-cell population after antigen-specific rechallenge., Conclusions: These results give an important indication of the mechanism by which FasL-expressing third-party cells can reduce an allospecific T-cell response by an apoptotic mechanism. Furthermore, they demonstrate that apoptotic tolerance in vivo may only occur after the prolonged period of potentially graft-damaging T-cell activation required for acquisition of sensitivity to Fas-mediated apoptosis.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.